Rocket One Inc. Common Stock (NASDAQ:RKTO) Stock Moved Up to “Sell” by Wall Street Zen

Wall Street Zen upgraded shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) from a strong sell rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings cut shares of Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Rocket One Inc. Common Stock presently has an average rating of “Hold” and an average target price of $5.00.

Rocket One Inc. Common Stock Price Performance

Shares of RKTO stock opened at $0.51 on Friday. Rocket One Inc. Common Stock has a 1-year low of $0.49 and a 1-year high of $2.45. The firm has a market cap of $11.32 million, a PE ratio of -0.62 and a beta of 0.90. The company has a 50-day moving average of $0.71 and a two-hundred day moving average of $0.83.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Rocket One Inc. Common Stock stock. Lido Advisors LLC boosted its holdings in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,000 shares of the company’s stock after buying an additional 19,500 shares during the quarter. Lido Advisors LLC owned 0.20% of Rocket One Inc. Common Stock worth $33,000 as of its most recent SEC filing. 7.08% of the stock is currently owned by institutional investors and hedge funds.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.